10x Genomics, Inc. filed a Form 8-K on November 2, 2026, disclosing the appointment of Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors, effective October 28, 2026.

Key Highlights

  • Two new directors appointed: Ansuman Satpathy and Joseph Gilliam joined the Board of Directors as Class III directors effective October 28, 2026, with terms expiring at the 2028 annual meeting of stockholders.
  • Satpathy's background: Dr. Satpathy has served as Associate Professor of Pathology and Immunology at Stanford University since April 2024 and as a venture partner at Wing Venture Capital since November 2021.
  • Gilliam's background: Mr. Gilliam has served as President and Chief Operating Officer of Glaukos Corporation since April 2022 and previously held senior roles at JPMorgan Chase and PricewaterhouseCoopers.
  • Audit Committee Chair: On October 30, 2026, Mr. Gilliam was appointed Chair of the Audit Committee, for which he will receive an annual retainer of $25,000, prorated as necessary.
  • Director compensation: Each new director will receive an annual cash retainer of $60,000, a one-time restricted stock unit grant with a target value of $400,000 on November 30, 2026, and an annual RSU grant with a target value of $215,000.
  • Prior advisor relationship: Dr. Satpathy had entered into a scientific advisor agreement with the company on December 13, 2024, under which he received 10,000 restricted stock units; that agreement was terminated in October 2026 prior to his board appointment.

Board Expansion at 10x Genomics: Satpathy and Gilliam Appointments Detailed

According to the filing, the Board of Directors of 10x Genomics, Inc. (NASDAQ:TXG), acting upon the recommendation of its Nominating and Corporate Governance Committee, appointed both directors effective immediately on October 28, 2026. The company disclosed that each director's term will expire at the 2028 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation, disqualification, or removal.

The filing describes Dr. Satpathy as a co-founder of four private life sciences companies - Immunai, Cartography Biosciences, Santa Ana Bio, and Arpelos Biosciences - focused on "data-driven and AI-enabled approaches to drug discovery in oncology and immunology." He also serves on the boards of a number of private life sciences companies and holds an M.D. and Ph.D. in Immunology from Washington University in St. Louis. The company stated it believes Dr. Satpathy is qualified due to "his extensive scientific and academic training, his deep expertise in genomics, immunology and data-driven approaches to drug discovery and his experience as a co-founder, director and investor in life sciences companies."

Mr. Gilliam's background, as described in the filing, spans healthcare investment banking at JPMorgan Chase from 2000 to 2017, followed by senior finance and operations roles at Glaukos Corporation. He currently sits on the board of Caris Life Sciences, where he also serves on the audit and compensation committees. The company stated it believes Mr. Gilliam is qualified because of "his senior management and financial leadership experience at a publicly traded medical technology company, his extensive background in healthcare investment banking and accounting and his public company board and audit committee experience." Each new director also entered into the company's standard indemnification agreement in connection with the appointment.

What Was Disclosed

10x Genomics disclosed the appointment of two Class III directors effective October 28, 2026, along with their qualifications, compensation terms under the Non-Employee Director Compensation Policy, and Mr. Gilliam's designation as Audit Committee Chair effective October 30, 2026.